IndustryCompany release

GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage

GH Research PLC (GHRS) · Fri 13 Nov 2026

The clinical-stage company says it will need substantial extra funding, while a Phase 1 trial supports a single fixed dose per visit of inhaled mebufotenin.

GH Research PLC has published its management discussion for the nine months ended 30 September 2026, reporting a loss of $46.6 million. The company, which is clinical-stage, is developing GH001, an inhaled form of mebufotenin, for treatment-resistant depression.

Its accumulated deficit stood at $200.0 million. GH Research said it will need substantial additional funding, a standard caveat for a company that has yet to bring a product to market.

On the clinical side, the company pointed to the Phase 1 trial GH001-HV-106. According to the summary of the disclosure, the study supports a single fixed dose per visit when GH001 is given with the company's proprietary aerosol delivery device.

That finding comes ahead of a planned global pivotal programme for GH001 in treatment-resistant depression. The material available does not give further detail on trial design, timelines, regulatory interactions or the size of the funding requirement.

What it means for your team

  • A fixed-dose-per-visit regimen with a proprietary aerosol device points to a drug-device combination, so teams should expect device-related considerations alongside the drug dossier.
  • The stated need for substantial extra funding is a factor for partners and payers assessing the long-term viability of the pivotal programme.
  • Detail on pivotal trial design and regulatory feedback was not available in the material reviewed; watch for further company disclosures.

Company's press release (SEC filing): GH Research PLC ↗

Article written by VigiEye from the official source (GH Research PLC). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →